At a glance
ClinicalIndex Comparison RecordN/ACompleted· 210 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Cohort Study of Patients With Metastatic Colorectal Cancer Treated With Avastin® as First-line Therapy for Liver Metastases Considered as Potentially Resectable
In Brief
An observational study evaluating Bevacizumab for Colorectal Cancer. Completed, enrolled 210 participants across 126 sites.
Detailed Summary
This observational study will evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedApr 2011
Primary CompletionJun 2015
TodayJul 2026
First PostedApr 28, 2011
Enrollment StartSep 30, 2010
Primary CompletionJun 30, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 15.2 years ago
Interventions
Bevacizumabdrug
Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.